Suppression of the chromatin remodeling protein CHD3 and platinum resistance in ovarian cancer

ABSTRACT: Epithelial ovarian cancer is the leading cause of death from gynecological malignancies. Currently platinum-based chemotherapy, coupled with a taxane based drug is the primary treatment for ovarian cancer. Approximately 25% of patients either present with or rapidly develop resistance to platinum based chemotherapy and all recurrent tumors ultimately become resistant. Epigenetic modifications have been associated with tumor formation and progression and may contribute to therapy response. We performed a methylation screen on a set of tumors and have found a number of genes and family members differentially methylated between resistant patients and sensitive patients. Here we show that loss of expression of CHD3, a member of the Mi-2/NuRD complex, causes increased resistance to platinum che

ORGANISM(S): Homo sapiens

SUBMITTER: Kazimierz Wrzeszczynski 

PROVIDER: E-GEOD-33011 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress